首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1475224

全球 PARP 抑制劑生物標記市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global PARP Inhibitor Biomarkers Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 238 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球 PARP 抑制劑生物標記市場需求預計將從 2023 年的 9,1123 萬美元達到 2,0,2032 萬美元的市場規模，2024 年至 2032 年研究期間複合年成長率為 9.25%。

PARP 抑制劑生物標記是識別可能對聚（ADP-核糖）聚合酶（PARP）抑制劑治療產生積極反應的癌症患者的分子標記。這些生物標記包括 DNA 修復途徑的基因突變或改變，例如 BRCA1 和 BRCA2 基因，以及與同源重組缺陷 (HRD) 或合成致死相關的其他基因。透過基因檢測或腫瘤組織的分子譜分析這些生物標記物，腫瘤學家可以確定PARP 抑制劑治療對個別患者的適用性，並客製化治療策略，以最大限度地提高卵巢癌、乳腺癌和前列腺癌的療效並最大限度地減少副作用。

市場動態

人們對癌症生物學和 DNA 損傷修復途徑在癌症進展中的作用的深入了解，推動了 PARP 抑制劑作為一類有前途的抗癌藥物的發展。隨著PARP 抑制劑在治療具有特定基因突變（如BRCA1 和BRCA2）的癌症方面顯示出療效，人們越來越需要能夠準確預測患者對PARP 抑制劑治療的反應並識別最有可能從治療中受益的個體的生物標記。此外，伴隨診斷和基因組分析技術的出現使得能夠識別與 PARP 抑制劑敏感性或抗藥性相關的生物標記物，從而促進患者分層和治療決策。此外，腫瘤學中擴大採用精準醫學方法，推動了對針對特定分子途徑和腫瘤特徵的生物標記驅動療法的需求，從而最大限度地減少與治療相關的毒性並最大限度地提高治療效果。

此外，生物標記發現技術的進步，包括次世代定序 (NGS)、基因表現譜和液體活體組織切片測定，能夠識別 PARP 抑制劑反應的新型預測生物標記物，從而擴大適合治療的潛在患者群體。隨著製藥公司投資開發 PARP 抑制劑和伴隨診斷，對生物標記驗證研究和監管部門批准用於 PARP 抑制劑治療的生物標記驅動的伴隨診斷的需求日益成長。此外，癌症發生率的上升和對個人化治療選擇的需求不斷增加推動了 PARP 抑制劑生物標記的市場。然而，隨著癌症診斷和治療領域的不斷發展，癌症研究的進步、新的治療方式和不斷變化的監管要求可能會在未來幾年挑戰 PARP 抑制劑生物標記市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球 parp 抑制劑生物標記市場的各個細分市場進行了包容性評估。 parp 抑制劑生物標記產業的成長和趨勢為本研究提供了整體方法。

市場區隔

parp 抑制劑生物標記市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按產品分類

套件
化驗

按服務分類

BRCA 1 和 2 測試
人力資源開發測試
HRR測試
其他

按申請

乳癌
卵巢癌
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲 PARP 抑制劑生物標記物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。 PARP抑制劑生物標記市場的主要參與者包括Myriad Genetics, Inc.、AmbryGenetics、Thermo Fisher Scientific Inc.、Illumina, Inc.、Centogene NV、廈門診斷有限公司、Invitae Corporation、NeoGenomics Laboratories.、Qiagen、Agilent Technologies , Inc. 本部分包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概覽、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：PARP 抑制劑生物標記公司的競爭格局

PARP抑制劑生物標記市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Myriad Genetics Inc.

公司簡介
公司收入
產品
最近的發展

AmbryGenetics

公司簡介
公司收入
產品
最近的發展

Thermo Fisher Scientific Inc.

公司簡介
公司收入
產品
最近的發展

Illumina Inc.

公司簡介
公司收入
產品
最近的發展

Centogene NV

公司簡介
公司收入
產品
最近的發展

Amoy Diagnostics Co. Ltd.

公司簡介
公司收入
產品
最近的發展

Invitae Corporation

公司簡介
公司收入
產品
最近的發展

NeoGenomics Laboratories.

公司簡介
公司收入
產品
最近的發展

Qiagen

公司簡介
公司收入
產品
最近的發展

Agilent Technologies Inc.

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114327

The global demand for PARP Inhibitor Biomarkers Market is presumed to reach the market size of nearly USD 2020.32 Million by 2032 from USD 911.23 Million in 2023 with a CAGR of 9.25% under the study period 2024 - 2032.

PARP inhibitor biomarkers are molecular markers that identify cancer patients likely to respond positively to treatment with poly (ADP-ribose) polymerase (PARP) inhibitors. These biomarkers include genetic mutations or alterations in DNA repair pathways, such as BRCA1 and BRCA2 genes, and other genes associated with homologous recombination deficiency (HRD) or synthetic lethality. By analyzing these biomarkers through genetic testing or molecular profiling of tumor tissues, oncologists can determine the suitability of PARP inhibitor therapy for individual patients and tailor treatment strategies to maximize efficacy and minimize side effects in ovarian, breast, and prostate cancer.

MARKET DYNAMICS

The spurring understanding of cancer biology and the role of DNA damage repair pathways in cancer progression drive the growth of PARP inhibitors as a promising class of anticancer agents. With PARP inhibitors showing efficacy in treating cancers with specific genetic mutations such as BRCA1 and BRCA2, there is a growing need for biomarkers that can accurately predict patient response to PARP inhibitor therapy and identify individuals most likely to benefit from treatment. Additionally, the emergence of companion diagnostics and genomic profiling technologies enables the identification of biomarkers associated with PARP inhibitor sensitivity or resistance, facilitating patient stratification and treatment decision-making. Moreover, the increasing adoption of precision medicine approaches in oncology drives the demand for biomarker-driven therapies that target specific molecular pathways and tumor characteristics, minimizing treatment-related toxicity and maximizing therapeutic efficacy.

Furthermore, advancements in biomarker discovery technologies, including next-generation sequencing (NGS), gene expression profiling, and liquid biopsy assays, enable the identification of novel predictive biomarkers for PARP inhibitor response, expanding the potential patient population eligible for treatment. With pharmaceutical companies investing in developing PARP inhibitors and companion diagnostics, there is a growing need for biomarker validation studies and regulatory approval of biomarker-driven companion diagnostics for PARP inhibitor therapy. Additionally, the rising incidence of cancer and the increasing demand for personalized treatment options drive the market for PARP inhibitor biomarkers. However, advancements in cancer research, new treatment modalities, and evolving regulatory requirements may challenge the PARP Inhibitor Biomarkers market growth in the coming years as the landscape of cancer diagnostics and therapeutics continues to grow.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of parp inhibitor biomarkers. The growth and trends of parp inhibitor biomarkers industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the parp inhibitor biomarkers market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Kits
Assays

By Services

BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others

By Application

Breast Cancer
Ovarian Cancer
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the PARP Inhibitor Biomarkers market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the PARP Inhibitor Biomarkers market include Myriad Genetics, Inc., AmbryGenetics, Thermo Fisher Scientific Inc., Illumina, Inc., Centogene N.V., Amoy Diagnostics Co., Ltd., Invitae Corporation, NeoGenomics Laboratories., Qiagen, Agilent Technologies, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.'

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PARP INHIBITOR BIOMARKERS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Services
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data
5.3. Analysis By Product
5.4. Kits Historic and Forecast Sales By Regions
5.5. Assays Historic and Forecast Sales By Regions

6. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY SERVICES

6.1. Overview By Services
6.2. Historical and Forecast Data
6.3. Analysis By Services
6.4. BRCA 1 & 2 Testing Historic and Forecast Sales By Regions
6.5. HRD Testing Historic and Forecast Sales By Regions
6.6. HRR Testing Historic and Forecast Sales By Regions
6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data
7.3. Analysis By Application
7.4. Breast Cancer Historic and Forecast Sales By Regions
7.5. Ovarian Cancer Historic and Forecast Sales By Regions
7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PARP INHIBITOR BIOMARKERS COMPANIES

9.1. PARP Inhibitor Biomarkers Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PARP INHIBITOR BIOMARKERS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Myriad Genetics Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. AmbryGenetics
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Thermo Fisher Scientific Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Illumina Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Centogene N.V.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Amoy Diagnostics Co. Ltd.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Invitae Corporation
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. NeoGenomics Laboratories.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Qiagen
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Agilent Technologies Inc.
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments